8-K current report · filed Nov 13, 2026

Revvity (RVTY) 8-K Current Report: November 13, 2026

Item 7.01Item EX-99.1Item EX-99.2RVTY overview

Short answer

Revvity (RVTY) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Investor Day 2026 features CEO Prahlad Singh and senior management updates.

Revvity 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Investor Day 2026 features CEO Prahlad Singh and senior management updates
  • Focus areas: key business initiatives, operational achievements and financial outlook
  • Investor presentation and press release furnished as Exhibits 99.1 and 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Investor Day outlines Revvity’s strategy for AI-enabled scientific discovery across Life Sciences and Diagnostics
  • Management reaffirmed a long-term goal of above-market growth and sustained shareholder value
  • Strategic priorities include organizational simplification, operational optimization and margin expansion
  • 2025 revenue totaled $2.9 billion, with approximately 11,000 employees serving customers in more than 160 countries

Item EX-99.2 · Exhibit EX-99.2

  • Investor Day presentation highlights 2026E revenue of approximately $2.9B, with 85% recurring revenue
  • Life Sciences 2026E revenue approximately $1.5B, Diagnostics approximately $1.4B
  • Signals Software 2026E revenue approximately $260M, with ARR above $275M and net retention around 107%
  • Strategic thesis: AI-driven discovery should increase demand for Revvity’s reagents, instruments and scientific software
  • Forecast framework excludes the China immunodiagnostics business pending divestiture, affecting comparability of 2026E metrics

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Revvity 8-K filings

Get the next RVTY 8-K as it lands

Follow RVTY for push alerts, or ask the research agent what this filing means.